Actionable insights straight to your inbox

Equities logo

Acceleron Pharma Shows Positive Phase 2 Data for Beta Thalassemia Therapy

Clinically meaningful increases in hemoglobin and reductions in red blood cell transfusion burden observed through 36 months.